Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Panel:   GN7F ARLN (Custom)
AR Bank # 0347 Klebsiella pneumoniae
Study ID: NEW-02

Biosample Accession #: SAMN11953775

mCIM Result: Positive    Carba NP Result: Positive


Panel:  Isolates with New or Novel Antibiotic Resistance (NEW)  |  ARLN Verification (Custom)  |  GAIHN (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 16R
Ampicillin >32R
Ampicillin/sulbactam 1>32R
Aztreonam >64R
Aztreonam/avibactam 14---
Cefazolin >8R
Cefepime >32R
Cefepime/zidebactam 54---
Cefotaxime >64R
Cefotaxime/clavulanic acid 1>32---
Cefoxitin >16R
Ceftazidime >128R
Ceftazidime/avibactam 1>16R
Ceftazidime/clavulanic acid 1>64---
Ceftolozane/tazobactam 1>16R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 40.5I
Doripenem >8R
Ertapenem >8R
Gentamicin 2S
Imipenem >64R
Imipenem+chelators 3>32---
Levofloxacin >8R
Meropenem >8R
Meropenem-vaborbactam 1>16R
Minocycline 16R
Omadacycline 232R
Piperacillin/tazobactam 1>128R
Plazomicin 1---
Tetracycline 16R
Tigecycline 24I
Tobramycin 16R
Trimethoprim/sulfamethoxazole 12S
MICs obtained by broth microdilution. Modal MIC is reported
S – I –R Interpretation (INT) derived from CLSI 2023 M100 S33
1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
5 Cefepime to zidebactam ratio (1:1)
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(6')-Ib, aph(3')-Ia
Beta-lactam KPC-3
Macrolide-Lincosamide-Streptogramin mph(A)
Trimethoprim dfrA14
 
Disclaimer:
The resistance mechanisms listed were identified by analysis of whole genome sequence using the ResFinder database (last updated June 2, 2016 and accessed on October 25, 2016). This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
01/08/24MIC was updated with a new value for Minocycline: from '---' to '16'
09/14/23INT was updated with a new value for Amikacin: from 'S' to 'R'
Top of Page
TOP